The Anti-inflammatory Effect of Erythromycin and its Derivatives, with Special Reference to Nasal Polyposis and Chronic Sinusitis
- 1 January 2001
- journal article
- research article
- Published by Taylor & Francis in Acta Oto-Laryngologica
- Vol. 121 (1) , 83-92
- https://doi.org/10.1080/000164801300006326
Abstract
Macrolides have been used for decades as an important chemotherapeutic agent in the treatment of infectious diseases. In the last 10 years there has also been increasing interest in the interaction between macrolide antibiotics and the immune system. The aim of this review is to focus on the anti-inflammatory action of erythromycin and its derivatives in the treatment of chronic sinusitis and nasal polyps. Systematic clinical investigations have been few and to the author's knowledge there have been no placebo-controlled studies. However there have been, especially from Japan, a number of clinical reports stating that long-term, low-dose macrolide antibiotics are effective in treating chronic sinusitis incurable by surgery or glucocorticosteroid treatment, with an improvement in symptoms varying between 60% and 80% in different studies. In animal studies macrolides have increased mucociliary transport, reduced goblet cell secretion and accelerated apoptosis of neutrophils, all factors that may reduce the symptoms of chronic inflammation. There is also increasing evidence in vitro of the anti-inflammatory effects of macrolides. Several studies have shown macrolides to inhibit interleukin gene expression for IL-6 and IL-8 and also to inhibit the expression of intercellular adhesion molecule essential for the recruitment of inflammatory cells. There is also evidence in vitro, as well as clinical experience, showing that macrolides reduce the virulence and tissue damage caused by chronic bacterial colonization without eradicating the bacteria. The benefit of long-term, low-dose macrolide treatment seems to be that it is, in selected cases, effective when steroids fail. The exact mechanism of action is not known, but it probably involves downregulation of the local host immune response as well as a downgrading of the virulence of the colonizing bacteria. In the future, placebo-controlled studies should be performed to establish the efficacy of macrolides if this treatment is to be accepted as evidence-based medicine.Keywords
This publication has 42 references indexed in Scilit:
- ‘Subinhibitory’ Erythromycin Represses Production of Pseudomonas aeruginosa Lectins, Autoinducer and Virulence FactorsChemotherapy, 1999
- A Macrolide Antibiotic, Roxithromycin, Inhibits the Growth of Nasal Polyp FibroblastsAmerican Journal of Rhinology, 1999
- Impact of endoscopic sinus surgery on global health perception: An outcomes studyOtolaryngology -- Head and Neck Surgery, 1998
- Evidence for Chlamydia pneumoniae Infection in Steroid-Dependent AsthmaAnnals of Allergy, Asthma & Immunology, 1998
- Myeloperoxidase and interleukin-8 levels in chronic sinusitisClinical and Experimental Allergy, 1997
- Erythromycin Suppresses Interleukin 6 Expression by Human Bronchial Epithelial Cells: A Potential Mechanism of Its Anti-inflammatory ActionBiochemical and Biophysical Research Communications, 1995
- Function and Activation of NF-kappaB in the Immune SystemAnnual Review of Immunology, 1994
- Comparison of Arachidonic Acid Metabolism in Nasal Polyps and EosinophilsInternational Archives of Allergy and Immunology, 1987
- Nasal polyps in asthma and rhinitis A review of 6,037 patientsJournal of Allergy and Clinical Immunology, 1977
- The use of macrolide antibiotic substances in the treatment of asthmaJournal of Allergy, 1970